Natriuretic peptides and cardio-renal disease

International Journal of Cardiology

Volumn 176, Issue 3, 2014, Pages 630-639

  Volpe, Massimo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Chronic kidney disease; Heart failure; Hypertension; Natriuretic peptide; Neprilysin

Indexed keywords

MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC FACTOR;

CARDIOVASCULAR DISEASE; ENERGY METABOLISM; HUMAN; KIDNEY DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR REMODELING;

CARDIOVASCULAR DISEASES; ENERGY METABOLISM; HUMANS; KIDNEY DISEASES; NATRIURETIC PEPTIDES; NEPRILYSIN; VASCULAR REMODELING;

EID: 84908156168     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.08.032     Document Type: Review

References (141)

1. KDIGO Clinical practice guideline for the evaluation and management of chronic kidney disease Available at: http://www.kdigo.org/clinical-practice-guidelines/ckd.php 2012
2. G. Mancia, R. Fagard, and K. Narkiewicz 2013 ESH/ESC guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 31 2013 1281 1357
3. J.J. McMurray, S. Adamopoulos, and S.D. Anker ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur Heart J 33 2012 1787 1847
4. T.G. von Lueder, and H. Krum RAAS inhibitors and cardiovascular protection in large scale trials Cardiovasc Drugs Ther 27 2013 171 179
5. C. Moro, and M. Lafontan Natriuretic peptides and cGMP signaling control of energy homeostasis Am J Physiol Heart Circ Physiol 304 2013 H358 H368
6. S. Nathisuwan, and R.L. Talbert A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure Pharmacotherapy 22 2002 27 42
7. S. Rubattu, S. Sciarretta, V. Valenti, R. Stanzione, and M. Volpe Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases Am J Hypertens 21 2008 733 741
8. R.S. Scotland, A. Ahluwalia, and A.J. Hobbs C-type natriuretic peptide in vascular physiology and disease Pharmacol Ther 105 2005 85 93
9. G.E. Woodard, and J.A. Rosado Natriuretic peptides in vascular physiology and pathology Int Rev Cell Mol Biol 268 2008 59 93
10. M. Kuhn Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A Circ Res 93 2003 700 709
11. L.R. Potter, A.R. Yoder, D.R. Flora, L.K. Antos, and D.M. Dickey Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications Handb Exp Pharmacol 191 2009 341 366
12. A. Clerico, F.A. Recchia, C. Passino, and M. Emdin Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications Am J Physiol Heart Circ Physiol 290 2006 H17 H29
13. B.S. Edwards, R.S. Zimmerman, T.R. Schwab, D.M. Heublein, and J.C. Burnett Jr. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor Circ Res 62 1988 191 195
14. S. Mangiafico, L.C. Costello-Boerrigter, I.A. Andersen, A. Cataliotti, and J.C. Burnett Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics Eur Heart J 34 2013 886-93c
15. K.N. Pandey Emerging roles of natriuretic peptides and their receptors in pathophysiology of hypertension and cardiovascular regulation J Am Soc Hypertens 2 2008 210 226
16. M. Kuhn Endothelial actions of atrial and B-type natriuretic peptides Br J Pharmacol 166 2012 522 531
17. O. Nakagawa, Y. Ogawa, and H. Itoh Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload J Clin Invest 96 1995 1280 1287
18. F. Macheret, D. Heublein, and L.C. Costello-Boerrigter Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP J Am Coll Cardiol 60 2012 1558 1565
19. S. Suga, H. Itoh, and Y. Komatsu Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells - evidence for CNP as a novel autocrine/paracrine regulator from endothelial cells Endocrinology 133 1993 3038 3041
20. E.R. Levin, D.G. Gardner, and W.K. Samson Natriuretic peptides N Engl J Med 339 1998 321 328
21. G. Boerrigter, and J.C. Burnett Recent advances in natriuretic peptides in congestive heart failure Expert Opin Investig Drugs 13 2004 643 652
22. R.A. Rose, and W.R. Giles Natriuretic peptide C receptor signalling in the heart and vasculature J Physiol 586 2008 353 366
23. S. Rubattu, S. Sciarretta, A. Morriello, C. Calvieri, A. Battistoni, and M. Volpe NPR-C: a component of the natriuretic peptide family with implications in human diseases J Mol Med 88 2010 889 897
24. S. Sciarretta, S. Marchitti, and F. Bianchi C2238 atrial natriuretic peptide molecular variant is associated with endothelial damage and dysfunction through natriuretic peptide receptor C signaling Circ Res 112 2013 1355 1364
25. F.R. Curry Atrial natriuretic peptide: an essential physiological regulator of transvascular fluid, protein transport, and plasma volume J Clin Invest 115 2005 1458 1461
26. K. Sabrane, M.N. Kruse, and L. Fabritz Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide J Clin Invest 115 2005 1666 1674
27. C. Calvieri, S. Rubattu, and M. Volpe Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides J Mol Med 90 2012 5 13
28. M. Briet, and K.D. Burns Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications Clin Sci (Lond) 123 2012 399 416
29. A. González, S. Ravassa, J. Beaumont, B. López, and J. Díez New targets to treat the structural remodeling of the myocardium J Am Coll Cardiol 58 2011 1833 1843
30. H.D. Intengan, and E.L. Schiffrin Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis Hypertension 38 3 Pt 2 2001 581 587
31. D. Hayashi, S. Kudoh, and I. Shiojima Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase phosphatase-1 Biochem Biophys Res Commun 322 2004 310 319
32. S. Fujita, N. Shimojo, and F. Terasaki Atrial natriuretic peptide exerts protective action against angiotensin II-induced cardiac remodeling by attenuating inflammation via endothelin-1/endothelin receptor A cascade Heart Vessels 28 2013 646 657
33. A. Calderone, C.M. Thaik, N. Takahashi, D.L. Chang, and W.S. Colucci Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts J Clin Invest 101 1998 812 818
34. P. Li, D. Wang, and J. Lucas Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts Circ Res 102 2008 185 192
35. A.M. Kapoun, F. Liang, and G. O'Young B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation Circ Res 94 2004 453 461
36. Y. Izumiya, S. Araki, H. Usuku, T. Rokutanda, S. Hanatani, and H. Ogawa Chronic C-type natriuretic peptide infusion attenuates angiotensin II-induced myocardial superoxide production and cardiac remodeling Int J Vasc Med 2012 2012 246058
37. K. Yamahara, H. Itoh, and T.H. Chun Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration Proc Natl Acad Sci 100 2003 3404 3409
38. T. Soeki, I. Kishimoto, and H. Okumura C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction J Am Coll Cardiol 45 2005 608 616
39. A.L. Birkenfeld, M. Boschmann, and J. Jordan Metabolic regulation: effects of natriuretic peptide interactions Expert Rev Endocrinol Metab 2 2007 607 614
40. C. Sengenès, M. Berlan, I. De Glisezinski, M. Lafontan, and J. Galitzky Natriuretic peptides: a new lipolytic pathway in human adipocytes FASEB J 14 2000 1345 1351
41. O. Tsukamoto, M. Fujita, and M. Kato Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure J Am Coll Cardiol 53 2009 2070 2077
42. A.L. Birkenfeld, M. Boschmann, and S. Engeli Atrial natriuretic peptide and adiponectin interactions in man PLoS ONE 7 2012 e43238
43. V. Cannone, G. Boerrigter, and A. Cataliotti A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community J Am Coll Cardiol 58 2011 629 636
44. M.T. Rademaker, and A.M. Richards Cardiac natriuretic peptides for cardiac health Clin Sci (Lond) 108 2005 23 36
45. T.G. von Lueder, S.J. Sangaralingham, and B.H. Wang Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure Circ Heart Fail 6 2013 594 605
46. A.J. Kenny, A. Bourne, and J. Ingram Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11 Biochem J 291 1993 83 88
47. Z. Abassi, E. Golomb, and H.R. Keiser Neutral endopeptidase inhibition increases the urinary excretion and plasma levels of endothelin Metabolism 41 1992 683 685
48. E.G. Erdös, and R.A. Skidgel Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones FASEB J 3 1989 145 151
49. L.J. Murphy, R. Corder, A.I. Mallet, and A.J. Turner Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and c-terminal fragment from big endothelin-1 Br J Pharmacol 113 1994 137 142
50. R.A. Skidgel, S. Engelbrecht, A.R. Johnson, and E.G. Erdös Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase Peptides 5 1984 769 776
51. S.L. Stephenson, and A.J. Kenny Metabolism of neuropeptides. Hydrolysis of the angiotensins, bradykinin, substance P and oxytocin by pig kidney microvillar membranes Biochem J 241 1987 237 247
52. J.P. Cooke The endothelium - a new target for therapy Vasc Med 5 2000 49 53
53. R. Corti, J.C. Burnett Jr., J.L. Rouleau, F. Ruschitzka, and T.F. Lüscher Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 104 2001 1856 1862
54. G.H. Gibbons Vascular remodeling in hypertension: role of autocrine-paracrine factors Blood Press Suppl 2 1995 49 54
55. P.R. Kalra, S.D. Anker, and A.J. Coats Water and sodium regulation in chronic heart failure: the ole of natriuretic peptides and vasopressin Cardiovasc Res 51 2001 495 509
56. P.R. Kalra, C. Anagnostopoulos, A.P. Bolger, A.J. Coats, and S.D. Anker The regulation and measurement of plasma volume in heart failure J Am Coll Cardiol 39 2002 1901 1908
57. M.E. Widlansky, N. Gokce, J.F. Keaney Jr., and J.A. Vita The clinical implications of endothelial dysfunction J Am Coll Cardiol 42 2003 1149 1160
58. D.G. Gardner, S. Chen, D.J. Glenn, and C.L. Grigsby Molecular biology of the natriuretic peptide system: implications for physiology and hypertension Hypertension 49 2007 419 426
59. K. Atarashi, P.J. Mulrow, and R. Franco-Saenz Effect of atrial peptides on aldosterone production J Clin Invest 76 1985 1807 1811
60. J.C. Burnett Jr., J.P. Granger, and T.J. Opgenorth Effects of synthetic atrial natriuretic factor on renal function and renin release Am J Physiol 247 1984 F863 F866
61. A. Luchner, and H. Schunkert Interactions between the sympathetic nervous system and the cardiac natriuretic peptide system Cardiovasc Res 63 2004 443 449
62. M. Volpe, A. Cuocolo, and F. Vecchione Vagal mediation of the effects of atrial natriuretic factor on blood pressure and arterial baroreflexes in the rabbit Circ Res 60 1987 747 755
63. M. Volpe, N. De Luca, and M. Cappelli Bigazzi Atrial natriuretic factor potentiates forearm reflex vasoconstriction induced by cardiopulmonary receptor deactivation in man Circulation 77 1988 849 855
64. G. Grassi Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions J Hypertens 19 2001 1713 1716
65. M. Bader Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy Annu Rev Pharmacol Toxicol 50 2010 439 465
66. J.L. Izzo Jr. The sympathetic nervous system in acute and chronic blood pressure elevation Oparil Weber Hypertension: companion to Brenner and Rector's the kidney 2nd ed. 2005 Elsevier Saunders Philadelphia 60 76
67. M. Volpe, N. DeLuca, and S.A. Atlas Reduction of atrial natriuretic factor circulating levels by endogenous sympathetic activation in hypertensive patients Circulation 77 1988 997 1002
68. S.A. Atlas The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition J Manag Care Pharm 13 Suppl. S-b 2007 S9 S20
69. M. Macía-Heras, N. Del Castillo-Rodríguez, and J.F. Navarro González The renin-angiotensin-aldosterone system in renal and cardiovascular disease and the effects of its pharmacological blockade J Diabetes Metab 3 2012 171
70. C. Rüster, and G. Wolf Renin-angiotensin-aldosterone system and progression of renal disease J Am Soc Nephrol 17 2006 2985 2991
71. T. Unger, L. Paulis, and D.A. Sica Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches Eur Heart J 32 2011 2739 2747
72. D.A. Calhoun Aldosterone and cardiovascular disease: smoke and fire Circulation 114 2006 2572 2574
73. W.N. Leimbach Jr., B.G. Wallin, R.G. Victor, P.E. Aylward, G. Sundlöf, and A.L. Mark Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure Circulation 73 1986 913 919
74. G. Grassi Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives Hypertension 54 2009 690 697
75. L.C. Rump, K. Amann, S. Orth, and E. Ritz Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uraemia? Nephrol Dial Transplant 15 2000 1735 1738
76. J.P. Fisher, and J.F. Paton The sympathetic nervous system and blood pressure in humans: implications for hypertension J Hum Hypertens 26 2012 463 475
77. R.W. Schrier, J.G. Abdallah, H.H. Weinberger, and W.T. Abraham Therapy of heart failure Kidney Int 57 2000 1418 1425
78. F. Triposkiadis, G. Karayannis, G. Giamouzis, J. Skoularigis, G. Louridas, and J. Butler The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications J Am Coll Cardiol 54 2009 1747 1762
79. G. Parati, and M. Esler The human sympathetic nervous system: its relevance in hypertension and heart failure Eur Heart J 33 2012 1058 1066
80. P. Palatini, E. Casiglia, and J. Gąsowski Arterial stiffness, central hemodynamics, and cardiovascular risk in hypertension Vasc Health Risk Manag 7 2011 725 739
81. B.M. Kaess, J. Rong, and M.G. Larson Aortic stiffness, blood pressure progression, and incident hypertension JAMA 308 2012 875 881
82. D.M. Pollock, and W.J. Adrendshorst Exaggerated natriuretic response to atrial natriuretic factor in rats developing spontaneous hypertension Hypertension 16 1990 72 79
83. S.W. John, J.H. Krege, and P.M. Oliver Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension Science 267 1995 679 681
84. G. Tonolo, A.M. Richards, and P. Manunta Low-dose infusion of atrial natriuretic factor in mild essential hypertension Circulation 80 1989 893 902
85. P. Belluardo, A. Cataliotti, and L. Bonaiuto Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy Am J Physiol Heart Circ Physiol 291 2006 H1529 H1535
86. C. Newton-Cheh, M.G. Larson, and R.S. Vasan Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure Nat Genet 41 2009 348 353
87. S. Masson, R. Latini, and I.S. Anand Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the valsartan heart failure (Val-HeFT) data Clin Chem 52 2006 1528 1538
88. N.S. Rost, A. Biffi, and L. Cloonan Brain natriuretic peptide predicts functional outcome in ischemic stroke Stroke 43 2012 441 445
89. E. Morita, H. Yasue, and M. Yoshimura Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction Circulation 88 1993 82 91
90. R.B. Schnabel, M.G. Larson, and J.F. Yamamoto Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community Circulation 121 2010 200 207
91. J. Fielitz, A. Dendorfer, and R. Pregla Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure Circulation 105 2002 286 289
92. W.H. Hörl Natriuretic peptides in acute and chronic kidney disease and during renal replacement therapy J Investig Med 53 2005 366 370
93. C.R. deFilippi, and R.H. Christenson B-type natriuretic peptide (BNP)/NT-proBNP and renal function: is the controversy over? Clin Chem 55 2009 1271 1273
94. K.S. Spanaus, F. Kronenberg, and E. Ritz B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the mild-to-moderate kidney disease study Clin Chem 53 2007 1264 1272
95. K. Yasuda, T. Kimura, and K. Sasaki Plasma B-type natriuretic peptide level predicts kidney prognosis in patients with predialysis chronic kidney disease Nephrol Dial Transplant 27 2012 3885 3891
96. M. Sakuma, M. Nakamura, and F. Tanaka Plasma B-type natriuretic peptide level and cardiovascular events in chronic kidney disease in a community-based population Circ J 74 2010 792 797
97. P.M. McKie, T. Ichiki, and J.C. Burnett Jr. M-atrial natriuretic peptide: a novel antihypertensive protein therapy Curr Hypertens Rep 14 2012 62 69
98. P.M. McKie, A. Cataliotti, T. Ichiki, S. Jeson Sangaralingham, H.H. Chen, and J.C. Burnett M-atrial natriuretic peptide and nitroglycerin in experimental acute hypertensive heart failure: differential actions of two cGMP activating therapeutics BMC Pharmacol Toxicol 14 Suppl. 1 2013 43
99. W.S. Colucci, U. Elkayam, and D.P. Horton Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group N Engl J Med 343 2000 246 253
100. J.D. Sackner-Bernstein, M. Kowalski, M. Fox, and K. Aaronson Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials JAMA 293 2005 1900 1905
101. J.D. Sackner-Bernstein, H.A. Skopicki, and K.D. Aaronson Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure Circulation 111 2005 1487 1491
102. C.M. O'Connor, R.C. Starling, and A.F. Hernandez Effect of nesiritide in patients with acute decompensated heart failure N Engl J Med 365 2011 32 43
103. A. Cataliotti, L.C. Costello-Boerrigter, H.H. Chen, S.C. Textor, and J.C. Burnett Jr. Sustained blood pressure-lowering actions of subcutaneous B-type natriuretic peptide (nesiritide) in a patient with uncontrolled hypertension Mayo Clin Proc 87 2012 413 415
104. O. Lisy, B.K. Huntley, D.J. McCormick, P.A. Kurlansky, and J.C. Burnett Jr. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP J Am Coll Cardiol 52 2008 60 68
105. H. Schweitz, P. Vigne, D. Moinier, C. Frelin, and M. Lazdunski A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps) J Biol Chem 267 1992 13928 13932
106. D.H. Dickey, and L.R. Potter Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation J Mol Cell Cardiol 51 2011 67 71
107. F.L. Martin, S.J. Sangaralingham, and B.K. Huntley CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart PLoS ONE 7 2012 e52422
108. X.W. Ng, Y. Huang, H.H. Chen, J.C. Burnett Jr., F.Y. Boey, and S.S. Venkatraman Cenderitide-eluting film for potential cardiac patch applications PLoS ONE 8 2013 e68346
109. C.Y. Lee, H.H. Chen, and O. Lisy Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects J Clin Pharmacol 49 2009 668 673
110. J. Neutel, W. Rolston, and S. Maddock Initial experience with subcutaneous infusion of cenderitide in chronic heart failure patients J Am Coll Cardiol 59 2012 E1037
111. J.R. Hirsch, M. Meyer, and W.G. Forssmann ANP and urodilatin: who is who in the kidney Eur J Med Res 11 2006 447 454
112. C. Lee, and J.C. Burnett Jr. Discovery of a novel synthetic natriuretic peptide, CU-NP J Card Fail 13 6 Suppl. 2 2007 S74
113. E.G. Bevan, J.M. Connell, and J. Doyle Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension J Hypertens 10 1992 607 613
114. A.M. Richards, G.A. Wittert, and I.G. Crozier Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II J Hypertens 11 1993 407 416
115. J.L. Rouleau, M.A. Pfeffer, and D.J. Stewart Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial Lancet 356 2000 615 620
116. J.B. Kostis, M. Packer, H.R. Black, R. Schmieder, D. Henry, and E. Levy Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial Am J Hypertens 17 2004 103 111
117. M. Packer, R.M. Califf, and M.A. Konstam Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) Circulation 106 2002 920 926
118. A.P. Kaplan Angioedema World Allergy Organ J 1 2008 103 113
119. R.M. Fryer, J. Segreti, and P.N. Banfor Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema Br J Pharmacol 153 2008 947 955
120. J. Gu, A. Noe, and P. Chandra Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) J Clin Pharmacol 50 2010 401 414
121. M.J. Bloch, and J.N. Basile Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone J Clin Hypertens (Greenwich) 12 2010 809 812
122. L.M. Ruilope, A. Dukat, M. Böhm, Y. Lacourcière, J. Gong, and M.P. Lefkowitz Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study Lancet 375 2010 1255 1266
123. N. Sun, F.-T. Chiang, and K. Kario Efficacy and safety of three doses of LCZ696 in Asian hypertensive patients: a randomized, double-blind, placebo-controlled study Oral presentation at 8th Asia-Pacific Congress of Hypertension (APCH), 24-27 November 2011, Taipei, Taiwan 2011
124. K. Kario, N. Sun, and F.T. Chiang Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension. A randomized, double-blind, placebo-controlled study Hypertension 63 2014 698 705
125. S. Toh, M.E. Reichman, and M. Houstoun Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system Arch Intern Med 172 2012 1582 1589
126. D.M. Lloyd-Jones, J.C. Evans, M.G. Larson, C.J. O'Donnell, E.J. Roccella, and D. Levy Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community Hypertension 36 2000 594 599
127. J.L. Izzo Jr., and B.E. Shykoff Arterial stiffness: clinical relevance, measurement, and treatment Rev Cardiovasc Med 2 29-34 2001 37 40
128. M.F. O'Rourke, M.E. Safar, and V. Dzau The cardiovascular continuum extended: aging effects on the aorta and microvasculature Vasc Med 15 2010 461 468
129. B. Williams Evolution of hypertensive disease: a revolution in guidelines Lancet 368 2006 6 8
130. S.G. Chrysant Current status of aggressive blood pressure control World J Cardiol 3 2011 65 71
131. W.B. Kannel, P.W. Wilson, B.H. Nam, R.B. D'Agostino, and J. Li A likely explanation for the J-curve of blood pressure cardiovascular risk Am J Cardiol 94 2004 380 384
132. C. Vlachopoulos, K. Aznaouridis, M.F. O'Rourke, M.E. Safar, K. Baou, and C. Stefanadis Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis Eur Heart J 31 2010 1865 1871
133. B. Williams, J.R. Cockcroft, and K. Kario The Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study design Poster presented at the 23rd European Meeting on Hypertension and Cardiovascular Protection, European Society of Hypertension (ESH), 14-17 June 2013, Milan, Italy 2013
134. S.D. Solomon, M. Zile, and B. Pieske The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial Lancet 380 2012 1387 1395
135. M. Komajda, P.E. Carson, and S. Hetzel Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE) Circ Heart Fail 4 2011 27 35
136. J.J. McMurray, M. Packer, and A.S. Desai Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure N Engl J Med 371 2014 993 1004
137. F. Böhm, and J. Pernow The importance of endothelin-1 for vascular dysfunction in cardiovascular disease Cardiovasc Res 76 2007 8 18
138. S. Laurent, M. Schlaich, and M. Esler New drugs, procedures, and devices for hypertension Lancet 380 2012 591 600
139. A. Parvanova, I. van der Meer, and I. Iliev Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial Lancet Diabetes Endocrinol 1 2013 19 27
140. P. Kalk, Y. Sharkovska, and E. Kashina Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner Hypertension 57 2011 755 763
141. Y. Sharkovska, P. Kalk, and K. von Websky Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage Clin Lab 57 2011 507 515